Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 6, 2013, Pages 874-880

  Giovanella, Luca ^a,b   Trimboli, Pierpaolo ^c   Verburg, Frederik A ^d   Treglia, Giorgio ^a   Piccardo, Arnoldo ^e   Foppiani, Luca ^e   Ceriani, Luca ^a  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^c Piazza San Bartolomeo All'Isola 21   (Italy)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e GALLIERA HOSPITAL   (Italy)

Author keywords

Differentiated thyroid carcinoma; Doubling time; Positron emission tomography; Thyroglobulin

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; THYROGLOBULIN; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; THYROXINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURGERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIATED THYROID CANCER; FALSE POSITIVE RESULT; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PET-CT SCANNER; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN BLOOD LEVEL; THYROIDECTOMY; TUMOR ABLATION; YOUNG ADULT; COST BENEFIT ANALYSIS; LUNG TUMOR; METABOLISM; METASTASIS; MULTIMODAL IMAGING; PATHOLOGY; RECURRENT DISEASE; THYROID TUMOR; TIME;

ADOLESCENT; ADULT; AGED; COST-BENEFIT ANALYSIS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RECURRENCE; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS; THYROXINE; TIME FACTORS;

EID: 84891558784     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2370-6     Document Type: Article

References (22)

1. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787-803.
2. Fatourechi V, Hay ID. Treating the patient with differentiated thyroid cancer with thyroglobulin-positive and iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance. Semin Nucl Med. 2000;30:107-14.
3. Freudenberg LS, Frilling A, Kühl H, Müller SP, Jentzen W, Bockisch A, et al. Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer. Eur Radiol. 2007;17:3139-47.
4. Iagaru A, Kalinyak JE, Mc Dougall IR. F-18 FDG PET/CT in the management of thyroid cancer. Clin Nucl Med. 2007;32:690-5.
5. Miller ME, Chen Q, Elashoff D, Abemayor E, St John M. Positron emission tomography and positron emission tomography-CT evaluation for recurrent papillary thyroid carcinoma: meta-analysis and literature review. Head Neck. 2011;33:562-5.
6. Lebolleaux S, Schroeder PR, Schlumberger M, Ladenson PV. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab. 2007;3:1112-21.
7. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-214.
8. Treglia G, Muoio B, Salvatori M, Giovanella L. The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview. Eur Arch Otorhinolaryngol. 2012. doi:10.1007/s00405-012-2205-2.
9. Menzel C, Zaplatnikov K, Diehl M, Döbert N, Hamscho N, Grünwald F. The influence of thyroglobulin on functional imaging in differentiated thyroid cancer. Nucl Med Commun. 2004;25:239-43.
10. Vera P, Kuhn-Lansoy C, Edet-Sanson A, Hapdey S, Modzweleski R, Hitzel A, et al. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin? Thyroid. 2010;20:15-23.
11. Giovanella L, Ceriani L, De Palma D, Suriano S, Castellani M, Verburg FA. Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas. Head Neck. 2012;34:626-31.
12. Bertagna F, Bosio G, Biasiotto G, Rodella C, Puta E, Gabanelli S, et al. F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level. Clin Nucl Med. 2009;34:756-61.
13. Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif BB, et al. 18FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med. 2007;48:221-6.
14. Miyauchi A, Kudo T, Miya A, Kobayashi K, Ito Y, Takamura Y, et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid. 2011;21:707-16.
15. Wong H, Wong KP, Yau T, Tang V, Leung R, Chiu J, et al. Is there a role for unstimulated thyroglobulin velocity in predicting recurrence in papillary thyroid carcinoma patients with detectable thyroglobulin after radioiodine ablation? Ann Surg Oncol. 2012;19:3479-85.
16. Greene FL, Gospodarowicz M, Wittekend C. American Joint Committee on Cancer (AJCC) staging manual. 7th ed. Philadelphia: Springer; 2009.
17. Giovanella L, Keller F, Ceriani L, Tozzoli R. Heterophile antibodies may falsely increase or decrease thyroglobulin measurement in patients with differentiated thyroid carcinoma. Clin Chem Lab Med. 2009;47:952-4.
18. Bidart M, Thullier F, Augereau C, Chalas J, Daver A, Jacob N, et al. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem. 1999;45:1695-707.
19. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1997;24:1342-8.
20. Schluter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med. 2001;42:71-6.
21. Freudenberg LS, Antoch G, Frilling A, Jentzen W, Rosenbaum SJ, Kühl H, et al. Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDGPET. Eur J Nucl Med Mol Imaging. 2008;35:950-7.
22. Luster M, KargesW, Zeich K, Pauls S, Verburg FA, Dralle H, et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid. 2010;20:527-33.